On July 7, WuXi XDC (02268.HK) declined 3.07% in regular trading, trading at HK$61.6/share, with turnover of HK$147 million.

On the news front, Morgan Stanley published a report on July 6 cutting WuXi XDC's target price from HK$83 to HK$80, while downgrading earnings forecasts for 2026 through 2030 by approximately 0-7%. The revision primarily reflects the consolidation of Dongyao Pharma's Q2 financials, which introduces lower gross margins and additional financial expenses, as well as the impact of USD depreciation against the RMB on exchange costs. Morgan Stanley maintained its Overweight rating on the stock.

The broader Life Sciences Tools and Services sector also traded weaker, with WuXi AppTec down 2.7%, WuXi Biologics down 2.17%, Insilico Medicine down 6.09%, and XtalPi down 3.79%, indicating broad-based sector pressure alongside the company-specific downgrade.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)